cytochrome c oxidase subunit 6C pseudogene 1Genealiases: []
Q-omics provides the consensus-scored COX6CP1 profile across patient tissues and cancer cell-line models. COX6CP1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, COX6CP1 is differentially expressed in 3, with the highest sampling consensus in BRCA. Additionally, COX6CP1 RNA expression shows 8,248 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, BRCA, and LSCC as cancer lineages where COX6CP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for COX6CP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes COX6CP1 survival associations across molecular data types. COX6CP1 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible COX6CP1 RNA expression–survival associations across cancer types. High COX6CP1 expression shows unfavorable associations in KIRC, LUAD, LIHC, OV and LUSC, but favorable associations in STAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .005). Together, the overview and detailed table identify KIRC as the clearest survival context for COX6CP1 RNA expression.
This table summarizes COX6CP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for COX6CP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. COX6CP1 shows higher tumor expression in BRCA, READ and STAD. The BRCA box plot shows higher COX6CP1 RNA expression in tumor versus normal tissue (log2 FC = +0.968, t-test p = .002).
This table shows molecular features associated with COX6CP1 in patient tissues and cancer cell lines. In patient samples, COX6CP1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
